RT Journal Article
SR Electronic
T1 Antibody Attributes that Predict the Neutralization and Effector Function of Polyclonal Responses to SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.06.21261710
DO 10.1101/2021.08.06.21261710
A1 Natarajan, Harini
A1 Xu, Shiwei
A1 Crowley, Andrew R.
A1 Butler, Savannah E.
A1 Weiner, Joshua A.
A1 Bloch, Evan M.
A1 Littlefield, Kirsten
A1 Benner, Sarah E.
A1 Shrestha, Ruchee
A1 Ajayi, Olivia
A1 Wieland-Alter, Wendy
A1 Sullivan, David
A1 Shoham, Shmuel
A1 Quinn, Thomas C.
A1 Casadevall, Arturo
A1 Pekosz, Andrew
A1 Redd, Andrew D.
A1 Tobian, Aaron A.R.
A1 Connor, Ruth I.
A1 Wright, Peter F.
A1 Ackerman, Margaret E.
YR 2021
UL http://medrxiv.org/content/early/2021/08/08/2021.08.06.21261710.abstract
AB While antibodies provide significant protection from SARS-CoV-2 infection and disease sequelae, the specific attributes of the humoral response that contribute to immunity are incompletely defined. In this study, we employ machine learning to relate characteristics of the polyclonal antibody response raised by natural infection to diverse antibody effector functions and neutralization potency with the goal of generating both accurate predictions of each activity based on antibody response profiles as well as insights into antibody mechanisms of action. To this end, antibody-mediated phagocytosis, cytotoxicity, complement deposition, and neutralization were accurately predicted from biophysical antibody profiles in both discovery and validation cohorts. These predictive models identified SARS-CoV-2-specific IgM as a key predictor of neutralization activity whose mechanistic relevance was supported experimentally by depletion. Validated models of how different aspects of the humoral response relate to antiviral antibody activities suggest desirable attributes to recapitulate by vaccination or other antibody-based interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Division of Intramural Research, NIAID, NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human subject research was approved by both the Johns Hopkins University School of Medicine Institutional Review Board and the Dartmouth-Hitchcock Medical Center Committee for the Protection of Human Subjects. All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code to reproduce analyses are available at (link pending).